Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma Advanced Research | BSE | Salute | Prodotti farmaceutici | 4,66 Bln INR | 44,8x | 1,84 | 1.940,25 INR | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -6,5% Ribasso | Fai l’upgrade a Pro+ | |
Sun Pharma AR | NSE | Salute | Prodotti farmaceutici | 4,65 Bln INR | 44,8x | 1,84 | 1.940,05 INR | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -6,1% Ribasso | Fai l’upgrade a Pro+ | |
Divis Laboratories | NSE | Salute | Prodotti farmaceutici | 1,43 Bln INR | 85x | 6,5 | 5.373,45 INR | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -13,7% Ribasso | Fai l’upgrade a Pro+ | |
Divis Laboratories | BSE | Salute | Prodotti farmaceutici | 1,42 Bln INR | 85x | 6,5 | 5.360,75 INR | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -13,7% Ribasso | Fai l’upgrade a Pro+ | |
Cipla | BSE | Salute | Prodotti farmaceutici | 1,34 Bln INR | 31,1x | 0,8 | 1.663,10 INR | 2,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 1,3% Rialzo | Fai l’upgrade a Pro+ | |
Cipla | NSE | Salute | Prodotti farmaceutici | 1,34 Bln INR | 31,1x | 0,8 | 1.668,25 INR | 2,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 1,3% Rialzo | Fai l’upgrade a Pro+ | |
Torrent Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 1,16 Bln INR | 67x | 1,84 | 3.418,10 INR | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2,3% Ribasso | Fai l’upgrade a Pro+ | |
Torrent Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 1,16 Bln INR | 67x | 1,84 | 3.399,70 INR | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -3% Ribasso | Fai l’upgrade a Pro+ | |
Dr Reddy’s Laboratories | NSE | Salute | Prodotti farmaceutici | 1,13 Bln INR | 20,1x | 1,12 | 6.755 INR | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,7% Ribasso | Fai l’upgrade a Pro+ | |
Dr Reddy’s Laboratories | BSE | Salute | Prodotti farmaceutici | 1,13 Bln INR | 20,1x | 1,12 | 6.734,10 INR | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,5% Ribasso | Fai l’upgrade a Pro+ | |
Mankind Pharma | BSE | Salute | Prodotti farmaceutici | 1,08 Bln INR | 40,9x | 1,58 | 2.630,50 INR | -2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -10% Ribasso | Fai l’upgrade a Pro+ | |
Mankind Pharma | NSE | Salute | Prodotti farmaceutici | 1,08 Bln INR | 40,9x | 1,58 | 2.625,60 INR | -2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -10,3% Ribasso | Fai l’upgrade a Pro+ | |
Zydus Lifesciences | BSE | Salute | Prodotti farmaceutici | 1,07 Bln INR | 25,5x | 0,38 | 1.058 INR | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,1% Rialzo | Fai l’upgrade a Pro+ | |
Zydus Lifesciences | NSE | Salute | Prodotti farmaceutici | 1,07 Bln INR | 25,5x | 0,38 | 1.060,55 INR | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,1% Rialzo | Fai l’upgrade a Pro+ | |
Apollo Hospitals | BSE | Salute | Fornitori e servizi sanitari | 1,03 Bln INR | 98,9x | 1,78 | 7.135,45 INR | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 1,7% Rialzo | Fai l’upgrade a Pro+ | |
Apollo Hospitals | NSE | Salute | Fornitori e servizi sanitari | 1,03 Bln INR | 98,9x | 1,78 | 7.149,55 INR | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 1,6% Rialzo | Fai l’upgrade a Pro+ | |
Lupin | NSE | Salute | Prodotti farmaceutici | 999,64 Mrd INR | 44,1x | 0,33 | 2.190,65 INR | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -6,3% Ribasso | Fai l’upgrade a Pro+ | |
Lupin | BSE | Salute | Prodotti farmaceutici | 998,29 Mrd INR | 44,1x | 0,33 | 2.192,90 INR | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -6,5% Ribasso | Fai l’upgrade a Pro+ | |
Max Healthcare Institute | NSE | Salute | Fornitori e servizi sanitari | 969,26 Mrd INR | 83,2x | -9,59 | 987,20 INR | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -4,5% Ribasso | Fai l’upgrade a Pro+ | |
Max Healthcare Institute | BSE | Salute | Fornitori e servizi sanitari | 969,26 Mrd INR | 83,2x | -9,59 | 984,90 INR | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -4,5% Ribasso | Fai l’upgrade a Pro+ | |
Aurobindo Pharma | NSE | Salute | Prodotti farmaceutici | 874,31 Mrd INR | 25,1x | 0,32 | 1.505,25 INR | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,2% Rialzo | Fai l’upgrade a Pro+ | |
Aurobindo Pharma | BSE | Salute | Prodotti farmaceutici | 871,81 Mrd INR | 25,1x | 0,32 | 1.502,45 INR | -0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7% Rialzo | Fai l’upgrade a Pro+ | |
Alkem Laboratories Ltd BO | BSE | Salute | Prodotti farmaceutici | 738,74 Mrd INR | 36x | 0,44 | 6.191,95 INR | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -3,7% Ribasso | Fai l’upgrade a Pro+ | |
Alkem Laboratories Ltd | NSE | Salute | Prodotti farmaceutici | 738,74 Mrd INR | 36x | 0,44 | 6.176,95 INR | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -4% Ribasso | Fai l’upgrade a Pro+ | |
Abbott India Ltd | BSE | Salute | Prodotti farmaceutici | 624 Mrd INR | 50,4x | 2,44 | 29.330,85 INR | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,1% Rialzo | Fai l’upgrade a Pro+ | |
Abbott India Ltd | NSE | Salute | Prodotti farmaceutici | 623,88 Mrd INR | 50,4x | 2,44 | 29.381,65 INR | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,1% Rialzo | Fai l’upgrade a Pro+ | |
Glenmark Pharmaceuticals | NSE | Salute | Prodotti farmaceutici | 475,37 Mrd INR | -36,3x | 0,05 | 1.685,40 INR | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -6,7% Ribasso | Fai l’upgrade a Pro+ | |
Glenmark Pharmaceuticals | BSE | Salute | Prodotti farmaceutici | 475,37 Mrd INR | -36,3x | 0,05 | 1.685,95 INR | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -6,8% Ribasso | Fai l’upgrade a Pro+ | |
Fortis Healthcare (India) | NSE | Salute | Fornitori e servizi sanitari | 463,92 Mrd INR | 71x | 5,41 | 614,35 INR | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -8,8% Ribasso | Fai l’upgrade a Pro+ | |
Fortis Healthcare (India) | BSE | Salute | Fornitori e servizi sanitari | 463,51 Mrd INR | 71x | 5,41 | 613,20 INR | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -8,7% Ribasso | Fai l’upgrade a Pro+ |